Anoro ellipta and Hyperventilation - a phase IV clinical study of FDA data

Summary:

Hyperventilation is reported as a side effect among people who take Anoro ellipta (umeclidinium bromide; vilanterol trifenatate), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Ventolin, and have Asthma.

The phase IV clinical study analyzes which people have Hyperventilation when taking Anoro ellipta. It is created by eHealthMe based on reports of 16,408 people who have side effects when taking Anoro ellipta from the FDA, and is updated regularly.

What is Anoro ellipta?

Anoro ellipta has active ingredients of umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 16,515 Anoro ellipta users. Check the latest studies of Anoro ellipta.

What is Hyperventilation?

Hyperventilation is found to be associated with 720 drugs and 1,441 conditions by eHealthMe. Check the latest studies of Hyperventilation.

On Jul, 04, 2026

16,408 people reported to have side effects when taking Anoro ellipta.
Among them, 20 people (0.12%) have Hyperventilation.

Could Anoro ellipta cause Hyperventilation?

Among these 20 people:

How long have people been on Anoro ellipta when they have Hyperventilation? *

What is the gender of people who have Hyperventilation when taking Anoro ellipta? *

female: 80 %
male: 20 %

What is the age of people who have Hyperventilation when taking Anoro ellipta? *

What are other drugs people take besides Anoro ellipta? *

What are other side effects people have besides Hyperventilation? *

Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi): 9 people, 45.00%
Drug Ineffective: 8 people, 40.00%
Cardiac Disorder: 8 people, 40.00%
Heart Rate Increased: 8 people, 40.00%
Exercise Tolerance Decreased: 8 people, 40.00%
The Flu (the flu is caused by an influenza virus): 8 people, 40.00%
Weakness: 7 people, 35.00%
Pneumonia: 7 people, 35.00%
Pneumonia Bacterial (pneumonia associated with bacterial infection): 6 people, 30.00%
Pleural Effusion (water on the lungs): 6 people, 30.00%

What are the existing conditions these people have? *

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 8 people, 40.00%
Asthma: 8 people, 40.00%
Neuropathy Peripheral (surface nerve damage): 6 people, 30.00%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 5.00%
Dyspnea (difficult or laboured breathing): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Anoro ellipta and have Hyperventilation?

- Check whether Hyperventilation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Anoro ellipta:

Anoro ellipta (16,515 reports)

Hyperventilation treatments and more:

Hyperventilation (8,309 reports)

How severe was Hyperventilation and when was it recovered:

Hyperventilation in Anoro ellipta

Expand to all the drugs that have ingredients of umeclidinium bromide; vilanterol trifenatate:

Hyperventilation and drugs with ingredients of umeclidinium bromide; vilanterol trifenatate (26 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Anoro ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperventilation:

Hyperventilation (720 drugs)

Browse all the conditions that are associated with Hyperventilation:

Hyperventilation (1,441 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on umeclidinium bromide; vilanterol trifenatate (the active ingredients of Anoro ellipta) and Anoro ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.